6 drug(s) with this reaction
20,238 total reports
Wrong Technique In Product Usage Process has been reported as an adverse reaction across 6 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 20,238 adverse event reports mention wrong technique in product usage process in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with wrong technique in product usage process, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have wrong technique in product usage process listed in their FDA adverse event reports, sorted by report count:
In addition to wrong technique in product usage process, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
6 drug(s) manufactured by Amgen Inc have wrong technique in product usage process listed in their FDA adverse event reports: PEGFILGRASTIM, ERENUMAB-AOOE, CINACALCET HYDROCHLORIDE, BLINATUMOMAB, ROMOSOZUMAB-AQQG, and others.
There are a combined 20,238 reports of wrong technique in product usage process across 6 Amgen Inc drug(s) in the FDA adverse event database.